(E)-3-(2-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl)prop-2-en-1-one | 1017898-63-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-(2-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl)prop-2-en-1-one
• 英文别名: (2E)-1-(2,4,6-trimethoxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one；(E)-1-(2,4,6-trimethoxyphenyl)-3-(2-nitrophenyl)prop-2-en-1-one；(E)-1-(2,4,6-trimethoxyphenyl)-3-(2-nitrophenyl)prop-2-en,1-one；(E)-3-(2-nitrophenyl)-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
• CAS: 1017898-63-3
• 化学式: C₁₈H₁₇NO₆
• 分子量: 343.336
• InChiKey: UOEZGUXMWHYVJQ-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-羟基-4,6-二甲氧基苯乙酮 在 potassium hydroxide 、 sodium hydroxide 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 48.0h， 生成 (E)-3-(2-nitrophenyl)-1-(2, 4, 6-trimethoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  三甲氧基查尔酮衍生物抑制巴西利什曼原虫的生长：合成，生物学评估，分子建模和结构-活性关系（SAR）

  摘要：

  在这项工作中，我们描述了一系列查尔酮衍生物的合成，抗菌活性以及分子建模和结构-活性关系（SAR）评估。在这些化合物中，甲氧基查耳酮2h，2i，2j，2k和2l表现出显着的抗菌活性（IC 50  <10μM）。有趣的是2i（IC 50  = 2.7μM），2j（IC 50  =  3.9μM ）和2k（IC 50 = 4.6μM）衍生物表现出比对照药物喷他idine（IC 50 = 6.0μM）。我们的SAR研究表明，在苯环A上进行甲氧基二邻取代的重要性以及这些分子的前沿轨道HOMO系数分布与其活性之间的关系。活性最高的化合物2h，2i，2j，2k和2l符合Lipinski的5法则，这在理论上对于良好的药物吸收和通过生物膜的渗透非常重要。2j的电位分布（IC 50  = 3.9μM，CC 50  = 216μM）表明，这种查耳酮衍生物是一种命中化合物，需要在抗衰老药物设计中进一步探索。

  DOI：

  10.1016/j.bmc.2011.06.023

文献信息

• Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: Quantitative structure–activity relationships
  作者：Louise Domeneghini Chiaradia、Rodrigo dos Santos、Carlos Eduardo Vitor、André Alexandre Vieira、Paulo César Leal、Ricardo José Nunes、João Batista Calixto、Rosendo Augusto Yunes

  DOI：10.1016/j.bmc.2007.10.039

  日期：2008.1

  induced enzymes involved is potentially an important strategy for obtaining antiinflammatory agents. In the search for hits to obtain lead compounds for new drugs of this class, 14 synthetic chalcones derived from 2,4,6-trimethoxyacetophenone were evaluated in terms of their inhibitory action, in vitro, in relation to NO production in murine macrophages of the line RAW 264.7 induced by bacterial lipopolysaccharides

  通过改变所涉及的诱导酶的表达来抑制一氧化氮（NO）的产生可能是获得抗炎药的重要策略。为了寻找此类新药的先导化合物，在寻找成功的途径中，评估了14种衍生自2,4,6-三甲氧基苯乙酮的合成查耳酮在体外对小鼠巨噬细胞NO生成的抑制作用。细菌脂多糖（LPS）诱导的RAW 264.7品系。所有化合物都是在碱性条件下通过苯乙酮与相应的醛之间的醛缩合获得的。在四个独立的实验中，通过剂量与抑制作用曲线计算出的平均IC（50）值在1.34至27.60microM之间变化，并与阳性对照化合物1400W（IC（50）= 3）进行了比较。78microM），一种高度选择性的iNOS抑制剂（诱导型一氧化氮合酶）。八个查耳酮的平均IC（50）值小于或等于1400W的平均IC（50）值，这表明这些分子可能充当炎症过程的抑制剂。QSAR研究表明，B环中的吸电子基团似乎增加了亚硝酸盐生成的抑制，主要是在2位时。A环的邻位取代似乎是活性所必需的。
• [EN] NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER<br/>[FR] MODULATEURS DE RÉCEPTEURS NUCLÉAIRES ET LEUR UTILISATION POUR LE TRAITEMENT ET LA PRÉVENTION D'UN CANCER
  申请人：US HEALTH

  公开号：WO2012174436A1

  公开（公告）日：2012-12-20

  Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

  本文披露了一些化合物，它们是核受体调节剂，可以作为雄激素受体的拮抗剂，例如，公式I的化合物：其中R1至R5和X1至X5如本文所述，以及其药用盐、溶剂化合物和立体异构体。还披露了包括这些化合物的药物组合物，以及使用方法和治疗癌症，包括前列腺癌、其他核受体介导的癌症和其他疾病的方法。
• Synthesis of Xanthohumol Analogues and Discovery of Potent Thioredoxin Reductase Inhibitor as Potential Anticancer Agent
  作者：Baoxin Zhang、Dongzhu Duan、Chunpo Ge、Juan Yao、Yaping Liu、Xinming Li、Jianguo Fang

  DOI：10.1021/jm5016507

  日期：2015.2.26

  The selenoprotein thioredoxin reductases (TrxRs) are attractive targets for anticancer drugs development. Xanthohumol (Xn), a naturally occurring polyphenol chalcone from hops, has received increasing attention because of its multiple pharmacological activities. We synthesized Xn and its 43 analogues and discovered that compound 13n displayed the highest cytotoxicity toward HeLa cells (IC50 = 1.4 mu M). Structure-activity relationship study indicates that the prenyl group is not necessary for cytotoxicity, and introducing electron-withdrawing group, especially on the meta-position, is favored. In addition, methylation of the phenoxyl groups generally improves the potency. Mechanistic study revealed that 13n selectively inhibits TrxR and induces reactive oxygen species and apoptosis in HeLa cells. Cells overexpressing TrxR are resistant to 13n insult, while knockdown of TrxR sensitizes cells to 13n treatment, highlighting the physiological significance of targeting TrxR by 13n. The clarification of the structural determinants for the potency would guide the design of novel potent molecules for future development.
• Chalcones with electron-withdrawing and electron-donating substituents: Anticancer activity against TRAIL resistant cancer cells, structure–activity relationship analysis and regulation of apoptotic proteins
  作者：Chun Wai Mai、Marzieh Yaeghoobi、Noorsaadah Abd-Rahman、Yew Beng Kang、Mallikarjuna Rao Pichika

  DOI：10.1016/j.ejmech.2014.03.002

  日期：2014.4

  In the present study, a series of 46 chalcones were synthesised and evaluated for antiproliferative activities against the human TRAIL-resistant breast (MCF-7, MDA-MB-231), cervical (HeLa), ovarian (Caov-3), lung (A549), liver (HepG2), colorectal (HT-29), nasopharyngeal (CNE-1), erythromyeloblastoid (K-562) and T-Iymphoblastoid (CEM-SS) cancer cells. The chalcone 38 containing an amino (-NH2) group on ring A was the most potent and selective against cancer cells. The effects of the chalcone 38 on regulation of 43 apoptosis-related markers in HT-29 cells were determined. The results showed that 20 apoptotic markers (Bad, Bax, BcI-2, Bcl-w, Bid, Bim, CD40, Fas, HSP27, IGF-1, IGFBP-4, IGFBP-5, Livin, p21, Survivin, 5TNE-R2, TRAIL-R2, XIAP, caspase-3 and caspase-8) were either up regulated or down regulated. (C) 2014 Elsevier Masson SAS.All rights reserved.
• CHALCONE DERIVATIVES AS NRF2 ACTIVATORS
  申请人：Biswal Shyam

  公开号：US20140088052A1

  公开（公告）日：2014-03-27

  Compounds and methods for treating or preventing a disease, disorder or condition associated with an Nrf2-regulated pathway, including those associated with an autoimmune disease, comorbidity associated with diabetes, such as retinopathy and nephropathy, bone marrow transplant for leukemia and related cancers, bone marrow deficiencies, inborn errors of metabolism, and other immune disorders, oxidative stress, respiratory infection, ischemia, neurodegenerative disorders, radiation injury, neutropenia caused by chemotherapy, autoimmunity, and congenital neutropenic disorders, and for restoring a corticosteroid responsiveness, in a subject are provided.